China’s fast-track clinical trials are in the spotlight after child deaths

In recent months, two children in China died after receiving gene-editing treatments in clinical trials, highlighting the country’s fast-track trial pathway. Investigator-initiated trials (IITs) allow researchers and biotech companies to test new therapies more quickly than through China’s official drug-approval system. These trials have contributed to China’s growing competitiveness in biomedicine, especially in cell and gene therapies. However, the deaths occurred shortly after China introduced stricter regulations for IITs, known as Order 818, which aims to enhance oversight while encouraging innovation. Previously, IITs were often conducted outside top hospitals, leading to a grey market with unauthorized therapies. Order 818 now mandates that only top-tier hospitals can conduct IITs for new biomedical technologies, ensuring better patient safety and research reliability. QUESTION: How might stricter regulations on clinical trials impact the development of new medical treatments in the future?